A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Pfizer
Pfizer
Merck Sharp & Dohme LLC
Eisai Inc.
Zhejiang DTRM Biopharma
Novartis
Bayer
Novartis
Veru Inc.
Eisai Inc.
Calithera Biosciences, Inc
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Genentech, Inc.
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis